Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice

Sodium-glucose co-transporter type 2 (SGLT2) inhibitor therapy to treat type 2 diabetes unexpectedly reduced all-cause mortality and hospitalization due to heart failure in several large-scale clinical trials, and has since been shown to produce similar cardiovascular disease-protective effects in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Bingxian, Ramirez, Wesley, Mills, Amanda M., Huckestein, Brydie R., Anderson, Moira, Pangburn, Martha M., Lang, Eric Y., Mullet, Steven J., Chuan, Byron W., Guo, Lanping, Sipula, Ian, O'Donnell, Christopher P., Wendell, Stacy G., Scott, Iain, Jurczak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9168377/
https://www.ncbi.nlm.nih.gov/pubmed/35677213
http://dx.doi.org/10.1016/j.crphys.2022.05.003

Ejemplares similares

Ejemplares similares